News
WindMIL Therapeutics Announces Marrow-Infiltrating Lymphocytes (MILs™) Data Selected for Poster Presentation at 61st American Society of Hematology Annual Meeting and Exposition

WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, announced today that data demonstrating the efficacy of chimeric antigen receptor (CAR) T cells developed using MILs (CAR-MILs) in comparison to peripheral blood lymphocytes has been selected for a poster at 61st American Society of Hematology (ASH) Annual Meeting and Exposition. ASH 2019 will […]

WindMIL Therapeutics to Present Data Demonstrating Marrow-Infiltrating Lymphocytes’ (MILs™) Superior Functionality Compared to Peripheral Blood Counterparts at 34th Annual Meeting of the Society for Immunotherapy of Cancer

WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, will present new data in a poster presentation on Saturday, November 9, 2019, at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), demonstrating that chimeric antigen receptor (CAR)-engineered MILs (CAR-MILs™) are more polyfunctional and produce higher levels of pro-inflammatory chemokines […]

WindMIL Therapeutics and University of California, Irvine Announce Collaboration to Collect Bone Marrow from Patients with Gliomas to Develop Marrow Infiltrating Lymphocytes (MILs™)

WindMIL Therapeutics and the University of California, Irvine (UCI) today announced that the first patients have been identified in an investigator-sponsored study for the collection of bone marrow from patients with gliomas. The study will evaluate generating marrow infiltrating lymphocytes (MILs™) for these patients through WindMIL’s proprietary cellular activation and expansion process. The study is […]

WindMIL Therapeutics Appoints Urvashi Patel, PhD, as Vice President of Regulatory & Quality Systems

WindMIL Therapeutics has announced the appointment of Urvashi Patel, PhD, as Vice President of Regulatory and Quality Systems. In this role, Dr. Patel will provide strategic vision and executional leadership for regulatory and quality functions and establish associated operations.

WindMIL Therapeutics and University of Michigan Announce Collaboration to Collect Bone Marrow from Patients with Head and Neck Cancer to Develop Marrow Infiltrating Lymphocytes (MILs™)

WindMIL Therapeutics (WindMIL) and the University of Michigan Rogel Cancer Center today announced that the first patients have been identified in an investigator-sponsored study for the collection of bone marrow from patients with head and neck squamous cell carcinoma (HNSCC).

WindMIL Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 2 Study of Marrow Infiltrating Lymphocytes (MILs™) in Non-Small Cell Lung Cancer

WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, announced today that it has been cleared by the U.S. Food and Drug Administration (FDA) to proceed with its Phase 2 study of MILs as a potential treatment for patients with non-small cell lung cancer (NSCLC) who have progressed on an anti-PD-1 containing […]

Endpoints: Peer Review: Don Hayden commits to CEO role at WindMIL; X4 nabs new CMO Lynne Kelley from Histogenics exile

Since leaving a 25-year career and the president of global pharmaceuticals title at Bristol-Myers Squibb in 2005, Don Hayden has kept himself busy as a consultant and adviser to biopharma companies, sometimes juggling seven or eight board appointments. But after a few months as interim CEO of WindMIL Therapeutics, he’s ready to “substantially pull back” on all those commitments as he transitions to a full-time role.

WindMIL Therapeutics Appoints Donald J. Hayden, Jr., as CEO

WindMIL Therapeutics has announced the appointment of Donald J. Hayden, Jr., as CEO.

Philadelphia Business Journal: Former Bristol-Myers Squibb executive named CEO of immunotherapy company

After spending the past four months as interim CEO of WindMIL Therapeutics, former Bristol-Myers Squibb executive Donald J. Hayden Jr. has accepted the position on a permanent basis.

FierceBiotech: WindMIL Therapeutics interim CEO Hayden steps up to the plate

When Donald Hayden, a 25-year veteran of Bristol-Myers Squibb, joined WindMIL Therapeutics as its executive chairman, he figured he would steer the ship until the company’s board picked a permanent CEO. But as he got to know the company and the marrow-infiltrating lymphocytes from which it takes its name, he “threw his hat into the […]